No time to die – BiGART is back. The 20th Acta Oncologica Symposium – BIGART 2021

References

• Grau C, Høyer M, Lindegaard J, et al. The emerging evidence for stereotactic body radiotherapy. Acta Oncol. 2006;45(7):771–774.
   PubMed Web of Science ®Google Scholar
• Grau C, Muren LP, Høyer M, et al. Image-guided adaptive radiotherapy - integration of biology and technology to improve clinical outcome. Acta Oncol. 2008;47(7):1182–1185.
   PubMed Web of Science ®Google Scholar
• Grau C, Olsen DR, Overgaard J, et al. Biology-guided adaptive radiation therapy - presence or future? Acta Oncol. 2010;49(7):884–887.
   PubMed Web of Science ®Google Scholar
• Grau C, Høyer M, Alber M, et al. Biology-guided adaptive radiotherapy (BiGART)-more than a vision? Acta Oncol. 2013;52(7):1243–1247.
   PubMed Web of Science ®Google Scholar
• Grau C, Overgaard J, Høyer M, et al. Biology-guided adaptive radiotherapy (BiGART) is progressing towards clinical reality. Acta Oncol. 2015;54(9):1245–1250.
   PubMed Web of Science ®Google Scholar
• Grau C, Høyer M, Poulsen PR, et al. Rethink radiotherapy - BIGART 2017. Acta Oncol. 2017;56(11):1341–1352.
   PubMed Web of Science ®Google Scholar
• Overgaard J, Muren LP, Høyer M, et al. BIGART 2019 - adapting to the future. Acta Oncol. 2019;58(10):1323–1327.
   PubMed Web of Science ®Google Scholar
• Engeseth GM, Hysing LB, Yepes P, et al. Impact of RBE variations on risk estimates of temporal lobe necrosis in patients treated with intensity-modulated proton therapy for head and neck cancer. Acta Oncol. 2022;61(2):215–222.
   PubMedGoogle Scholar
• Hahn C, Ödén J, Dasu A, et al. Towards harmonizing clinical linear energy transfer (LET) reporting in proton radiotherapy: a European multi-centric study. Acta Oncol. 2022;61(2):206–214.
   PubMedGoogle Scholar
• Sørensen BS, Pawelke J, Bauer J, et al. Does the uncertainty in relative biological effectiveness affect patient treatment in proton therapy? Radiother Oncol. 2021;163:177–184.
   PubMed Web of Science ®Google Scholar
• Fuglsang Jensen M, Stick LB, Høyer M, et al. Proton therapy for early breast cancer patients in the DBCG proton trial: planning, adaptation, and clinical experience from the first 43 patients. Acta Oncol. 2022;61(2):223–230.
   PubMedGoogle Scholar
• Bertelsen AS, Schytte T, Møller PK, et al. First clinical experiences with a high field 1.5 T MR linac. Acta Oncol. 2019;58(10):1352–1357.
   PubMed Web of Science ®Google Scholar
• Christiansen RL, Johansen J, Zukauskaite R, et al. Accuracy of automatic structure propagation for daily magnetic resonance image-guided head and neck radiotherapy. Acta Oncol. 2021;60(5):589–597.
   PubMed Web of Science ®Google Scholar
• Porraa L, Seppäläa T, Wendlanda L, et al. Accelerator-based boron neutron capture therapy facility at the Helsinki university hospital. Acta Oncol. 2022;61(2):269–273.
   Google Scholar
• Grau C, Defourny N, Malicki J, HERO consortium, et al. Radiotherapy equipment and departments in the european countries: final results from the ESTRO-HERO survey. Radiother Oncol. 2014;112(2):155–164.
   PubMed Web of Science ®Google Scholar
• Lievens Y, Borras JM, Grau C. Provision and use of radiotherapy in Europe. Mol Oncol. 2020;14(7):1461–1469.
   PubMed Web of Science ®Google Scholar
• Aggarwal A, Lewison G, Rodin D, et al. Radiation therapy research: a global analysis 2001-2015. Int J Radiat Oncol Biol Phys. 2018;101(4):767–778.
   PubMed Web of Science ®Google Scholar
• Witt Nyström P, Bratland Å, Minn H, et al. Ongoing and future clinical trials in particle therapy in the nordic countries. Acta Oncol. 2020;59(10):1145–1150.
   PubMed Web of Science ®Google Scholar
• Troost EGC, Menkel S, Tschiche M, et al. Towards online adaptive proton therapy: first report of plan-librarybased plan-of-the-day approach. Acta Oncol. 2022;61(2):231–234.
   PubMedGoogle Scholar
• Knuth F, Adde IA, Huynh BN, et al. MRI-based automatic segmentation of rectal cancer using 2D U-Net on two independent cohorts. Acta Oncol. 2022;61(2):255–263.
   PubMedGoogle Scholar
• Milo MLH, Nyeng TB, Lorenzen EL, et al. Atlas-based auto-segmentation for delineating the heart and cardiac substructures in breast cancer radiation therapy. Acta Oncol. 2022;61(2):247–254
   PubMedGoogle Scholar
• Baumann M, Ebert N, Kurth I, et al. What will radiation oncology look like in 2050? A look at a changing professional landscape in Europe and beyond. Mol Oncol. 2020;14(7):1577–1585.
   PubMed Web of Science ®Google Scholar
• Baumann M, Krause M, Overgaard J, et al. Radiation oncology in the era of precision medicine. Nat Rev Cancer. 2016;16(4):234–249.
   PubMed Web of Science ®Google Scholar
• Linge A, Lohaus F, Löck S, DKTK-ROG, et al. HPV status, cancer stem cell marker expression, hypoxia gene signatures and tumour volume identify good prognosis subgroups in patients with HNSCC after primary radiochemotherapy: a multicentre retrospective study of the german cancer consortium radiation oncology group (DKTK-ROG). Radiother Oncol. 2016;121(3):364–373.
   PubMed Web of Science ®Google Scholar
• Alsner J, Overgaard J, Tramm T, et al. Hypoxic gene expression is a prognostic factor for disease free survival in a cohort of locally advanced squamous cell cancer of the uterine cervix. Acta Oncol. 2022;61(2):172–178.
   PubMedGoogle Scholar
• Petersen SE, Thorsen LB, Hansen S, et al. A phase I/II study of acute and late physician assessed and patient-reported morbidity following whole pelvic radiation in high-risk prostate cancer patients. Acta Oncol. 2022;61(2):179–184.
   PubMedGoogle Scholar
• Abravan A, Salem A, Price G, et al. Effect of systemic inflammation biomarkers on overall survival after lung cancer radiotherapy. Acta Oncol. 2022;61(2):163–171.
   PubMedGoogle Scholar
• Tramm T, Vinter H, Vahl P, et al. Tumor-infiltrating lymphocytes predicts improved overall survival after post-mastectomy radiotherapy: a study of the randomized DBCG82bc cohort. Acta Oncol. 2022;61(2):153–162.
   PubMedGoogle Scholar
• van de Water S, Safai S, Schippers JM, et al. Towards FLASH proton therapy: the impact of treatment planning and machine characteristics on achievable dose rates. Acta Oncol. 2019;58(10):1463–1469.
   PubMed Web of Science ®Google Scholar
• Henry T, Bassler N, Ureba A, et al. Development of an interlaced-crossfiring geometry for proton grid therapy. Acta Oncol. 2017;56(11):1437–1443.
   PubMed Web of Science ®Google Scholar